Index · Artikel · J&J mulls sale of diagnostics unit

J&J mulls sale of diagnostics unit

2013-01-22 2
   
Advertisement
résumén">Johnson & Johnson may sell or spin off its slow-growing $2 billion-a-year diagnostics business, the company said on Tuesday when it reported quarterly earnings. The diversified healthcare company said it may sell the Ortho Clinical Diagnost
Advertisement

J&J mulls sale of diagnostics unit


n">Johnson & Johnson may sell or spin off its slow-growing $2 billion-a-year diagnostics business, the company said on Tuesday when it reported quarterly earnings.

The diversified healthcare company said it may sell the Ortho Clinical Diagnostics business - whose products include equipment for laboratory diagnostics and blood transfusion screening - or turn it into a stand-alone company.

The decision comes as drugmakers are shedding businesses and cutting costs due to overseas price controls and pressure on payments from insurers and the government. Pfizer Inc, for instance, is spinning off its animal health products business, and Abbott Laboratories has split off its drugs unit.

Debbie Wang, an analyst with Morningstar, said the J&J diagnostics unit "is a slower grower, and if you're not one of the leaders, it's very difficult to compete in that area."

Les Funtleyder, a fund manager at Poliwogg, said the company is wise to consider exiting this low-tech diagnostic business.

J&J should target the more high-tech, high-profit molecular diagnostics business, which entails sophisticated genetic analysis used by physicians to tailor treatment to individual patients, he said. This is becoming more of a mainstay in medical treatment, especially in cancer, where numerous gene mutations make patients vulnerable to disease.

"If you look five years down the road, we are going to see molecular diagnostics and gene sequencing converge," Funtleyder said in an interview at the J&J analyst meeting in New York. He added that gene sequencing - a process that looks for certain genes, and gene mutations especially, that predispose a person to certain diseases - will become the main determinant of how physicians treat patients.

Funtleyder said he thinks J&J should consider acquiring companies like Illumina Inc or Life Technologies Corp, both engaged in genetic analysis.

But Andy Busser, a fund manager for Symphony Capital in New York, thinks moving into molecular diagnostics may not be likely. "At the end of the day, they might prefer to invest that capital elsewhere."

Ortho Clinical Diagnostics, whose revenue growth has been relatively flat, is No. 5 in the clinical diagnostics market, as measured in sales. Typically, J&J's businesses rank first or second in their respective markets.

Clinical diagnostics is less attractive than molecular diagnostics, which might see near double-digit revenue growth in coming years, according to analysts.

It might be easier to sell Ortho Clinical Diagnostics to a private equity buyer, Funtleyder said. "They might be satisfied with a dependable if not an exciting business."

J&J, which made the disclosure as it reported stronger-than-expected earnings, said it was in the very early stages of examining options.

J&J said it earned $1.19 per share, excluding one-time items, in the fourth quarter, beating analysts' average estimate of $1.17.

A favorable tax rate and cost controls boosted results, according to Piper Jaffray analyst Matt Miksic. He also cited very strong growth in sales of J&J's traditional artificial hips and of artificial knees, whose combined U.S. sales rose 7 percent despite disruptions from Superstorm Sandy in the quarter.

CHARGES FOR HIP IMPLANTS

Including a charge of $800 million, related mostly to recalls of defective "metal-on-metal" hip replacement devices made by its DePuy Orthopedics unit, J&J earned $2.6 billion, or 91 cents per share. That compared with $218 million, or 8 cents per share, a year earlier, when the company took charges of more than $3 billion, including $800 million for medical costs related to the same recalls.

All-metal hip implants were developed to be more durable than traditional implants but have failed at a high rate. In some cases, they have shed metal fragments that have disabled patients. Traditional implants combine a ceramic or metal ball with a plastic socket.

As many as 500,000 Americans are estimated to have received metal-on-metal hip replacements in the last five years, with J&J the largest manufacturer of such products.

The company withdrew its ASR metal-on-metal hip system in 2010 and faces more than 2,000 lawsuits from patients claiming to have been harmed by it.

REVENUE UP BUT MISSES

J&J said global revenue rose 8 percent to $17.56 billion in the fourth quarter, below Wall Street expectations of $17.7 billion.

"The sales miss was driven by lower-than-expected medical device and consumer sales," RBC Capital Markets analyst Glenn Novarro said in a research note.

Sales of prescription drugs jumped 7 percent to $6.52 billion, helped by strong sales of its treatments for arthritis, psoriasis and HIV.

"By any measure, we have transformed our pharmaceuticals business," Chief Executive Alex Gorsky told analysts on a conference call. The business is bouncing back after several years of anemic sales due to generic competition for some of its top medicines.

But J&J said it expects its blockbuster Concerta treatment for attention deficit disorder to face pressure from cheaper generics early this year.

Fourth-quarter sales of medical devices rose almost 14 percent to $7.38 billion, boosted by the company's recent acquisition of trauma-device maker Synthes.

Sales of J&J's array of consumer products fell almost 3 percent to $14.4 billion, hurt by the stronger dollar and recalls of Tylenol and other over-the-counter medicines that have curtailed availability of the brands.

The company forecast full-year 2013 earnings of $5.35 to $5.45 per share, excluding special items. Analysts, on average, expected $5.49, according to Thomson Reuters I/B/E/S. The company is known for making conservative forecasts at the beginning of the year.

J&J shares were down 0.8 percent at $72.66 on Tuesday afternoon.

(Reporting by Ransdell Pierson in New York, Debra Sherman in Chicago and Caroline Humer in New York; editing by Maureen Bavdek, John Wallace and Matthew Lewis)

TOP

  • Day/
  • Week/
  • Original/
  • Recommand

Updated

  • Obama launches new push for healthcare overhaul

    Obama launches new push for healthcare overhaul
    WASHINGTON President Barack Obama on Saturday renewed his pitch for final congressional passage of a U.S. healthcare overhaul and promised Americans they will begin reaping the benefits soon after he signs a bill into law. As Obama's fellow Democrats
  • Small business group joins health reform lawsuit

    Small business group joins health reform lawsuit
    WASHINGTON An influential small business lobby group said on Friday it had joined 20 states in a lawsuit arguing insurance coverage requirements in the newly enacted healthcare overhaul are unconstitutional. The National Federation of Independent Bus
  • Ruddy Enten: The Original Butter Türkei

    Ruddy Enten: The Original Butter Türkei
    Holly A. Heyser "Hier kommen sie wieder!" Zwei Enten waren bereits nach unten im Wasser, und die 25-oder-so übrigen Mitglieder der Herde war eingekreist zurück und wurden Zoomen in Richtung unserer blinden wieder. Ich war nicht in der Lage zu sc
  • Wird eine Dosis von stromectal Arbeit?

    Ich las, dass stromectal nur Krätze tötet, die nach dosing.What über die Eier beißen? Es dauerte 15 Monate und eine ansteckende Krankheit, Arzt zu diagnostizieren me.I zu drei dermotologists ging, der sagte, dass ich nicht Krätze hatte, obwohl ich di
  • Plymouth Ventures schließt für die zweite Fonds $ 16M, der Suche nach mehr

    Plymouth Ventures schließt für die zweite Fonds $ 16M, der Suche nach mehr
    Plymouth Venture Partners hat sich auf 16.000.000 $ geschlossen und hofft, mindestens doppelt so hoch Menge , bevor sie Geld für ihren zweiten Fonds getan zu erhöhen. Nach dem $ 16.000.000 Nähe in einem Zulassungsantrag offenbart wurde, CEO Mark Horn
  • Überprüfen Sie Ihre Schränke: Selleriesamen Erinnerte auf Salmonellen Fears

    Überprüfen Sie Ihre Schränke: Selleriesamen Erinnerte auf Salmonellen Fears
    O Organics Bio - Selleriesamen und Swanson Bio - Selleriesamen (ganz) sind an allen Safeway eigenen Läden verkauft, darunter Dominicks WASHINGTON (Reuters) - B & M Inc O Organics Bio-Selleriesamen in Safeway Läden wegen möglicher Salmonellen Kontamin
  • Drei gemeinsame Indoor-Allergie-Mythen Busted

    Drei gemeinsame Indoor-Allergie-Mythen Busted
    Stephanie Rolfe geht ihr Hund Harry in der Nähe von ihrem Haus in Grove City, Ohio. Rolfe kaufte einen Hund, der kürzere Haare hat und wirft weniger als andere Rassen, dachte, es könnte sie Allergien lindern. Doch die Ärzte an der Ohio State Universi
  • Belastungs Kompartmentsyndrom

    Belastungs Kompartmentsyndrom
    Anstrengungsbedingtem Kompartmentsyndrom, auch bei körperlicher Anstrengung Kompartmentsyndrom und chronische Kompartmentsyndrom genannt, ist eine Erkrankung, die Muskelschmerzen verursacht. Die Patienten leiden typischerweise die Schmerzen nach eine
  • Restless-Legs-Syndrom - ich RLS ziemlich stark sind. An dieser Stelle nehme ich 2 Pramipexol 0,25 in?

    ... Die Uhr, die Uhr und 1 vor dem Schlafen 2in und ich bin immer noch Attacken. Ich habe auch vor kurzem Leiden mit meinen Armen Rucken und Zucken. Fühlen Ich brauche ein anderes Medikament, aber meine Dr. zögert. Sollte ich mehr Pramipexol? ----sch
  • Ways Menschen mit PTBS kann Gedächtnisverlust verhindern

    Ways Menschen mit PTBS kann Gedächtnisverlust verhindern
    Viele Menschen mit posttraumatischen Belastungsstörung (PTSD) haben Schwierigkeiten sich zu konzentrieren oder haben andere Probleme mit ihrem Gedächtnis, wie Gedächtnisverlust. In der Tat, das Gedächtnis und Konzentrationsstörungen sind häufige Symp